NASDAQ:MLYS Mineralys Therapeutics (MLYS) Stock Price, News & Analysis → AI healthcare stock poised for 36,996% growth? (From Behind the Markets) (Ad) Free mlys Stock Alerts $12.91 +0.13 (+1.02%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$12.74▼$13.1450-Day Range$8.27▼$16.1552-Week Range$5.85▼$17.70Volume66,761 shsAverage Volume171,890 shsMarket Capitalization$640.72 millionP/E RatioN/ADividend YieldN/APrice Target$37.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Mineralys Therapeutics alerts: Email Address Mineralys Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside186.6% Upside$37.00 Price TargetShort InterestHealthy5.75% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.98Based on 11 Articles This WeekInsider TradingAcquiring Shares$7.50 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.64) to ($3.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.00 out of 5 starsMedical Sector398th out of 938 stocksPharmaceutical Preparations Industry182nd out of 425 stocks 3.5 Analyst's Opinion Consensus RatingMineralys Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $37.00, Mineralys Therapeutics has a forecasted upside of 186.6% from its current price of $12.91.Amount of Analyst CoverageMineralys Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.75% of the float of Mineralys Therapeutics has been sold short.Short Interest Ratio / Days to CoverMineralys Therapeutics has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Mineralys Therapeutics has recently decreased by 13.54%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMineralys Therapeutics does not currently pay a dividend.Dividend GrowthMineralys Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MLYS. Previous Next 3.9 News and Social Media Coverage News SentimentMineralys Therapeutics has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Mineralys Therapeutics this week, compared to 1 article on an average week.Search Interest5 people have searched for MLYS on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows1 people have added Mineralys Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mineralys Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,499,992.00 in company stock and sold $0.00 in company stock.Percentage Held by Institutions84.46% of the stock of Mineralys Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Mineralys Therapeutics are expected to decrease in the coming year, from ($2.64) to ($3.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mineralys Therapeutics is -6.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mineralys Therapeutics is -6.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMineralys Therapeutics has a P/B Ratio of 2.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsAI healthcare stock poised for 36,996% growth?Buy Alert Issued For AI Small Cap Our last two AI stocks jumped 150% and 130%... But we just issued a brand new "buy alert" for a new one...Get the name of the stock here... About Mineralys Therapeutics Stock (NASDAQ:MLYS)Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Read More MLYS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MLYS Stock News HeadlinesMarch 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for Mineralys Therapeutics Amid Positive Clinical and Strategic DevelopmentsMarch 22, 2024 | finance.yahoo.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | Crypto 101 Media (Ad)Major Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.March 21, 2024 | msn.comMineralys Therapeutics files for $500M mixed shelf offeringMarch 21, 2024 | finance.yahoo.comMineralys Therapeutics Inc (MLYS) Reports Increased R&D Expenses Amid Progress in ...March 21, 2024 | seekingalpha.comMineralys Therapeutics, Inc. 2023 Q4 - Results - Earnings Call PresentationMarch 21, 2024 | globenewswire.comMineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 20, 2024 | finance.yahoo.comMLYS Jun 2024 12.500 callMarch 28, 2024 | Crypto 101 Media (Ad)Major Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.March 20, 2024 | finance.yahoo.comMLYS Sep 2024 30.000 callMarch 20, 2024 | benzinga.comMineralys Therapeutics Earnings PreviewMarch 19, 2024 | americanbankingnews.comMineralys Therapeutics (MLYS) to Release Earnings on ThursdayMarch 18, 2024 | msn.comMineralys Therapeutics Set to Release Q4 and Full-Year 2023 Financial Results, Eyes on Future Growth ProspectsMarch 18, 2024 | seekingalpha.comMineralys Therapeutics: A Story To Keep An Eye OnMarch 16, 2024 | finance.yahoo.comMLYS Apr 2024 15.000 callMarch 16, 2024 | finance.yahoo.comMLYS Mar 2024 20.000 callMarch 13, 2024 | globenewswire.comMineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024March 4, 2024 | benzinga.comMineralys Therapeutics Stock (NASDAQ:MLYS) Dividends: History, Yield and DatesFebruary 9, 2024 | seekingalpha.comMineralys: 2nd Half 2024 Hypertension Data ReadoutFebruary 9, 2024 | bizjournals.comMineralys Therapeutics set to raise $120M from investors to develop treatment for high blood pressureFebruary 9, 2024 | msn.comMineralys Therapeutics Equity Sales: Investor Impact ReportFebruary 9, 2024 | msn.comMineralys Therapeutics Announces Strategic Purchase AgreementFebruary 8, 2024 | msn.comMineralys Therapeutics stock jumps on $120M private placement financingFebruary 8, 2024 | finance.yahoo.comMineralys Therapeutics Announces $120 Million Private Placement FinancingJanuary 29, 2024 | finance.yahoo.comMineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology ConferenceJanuary 17, 2024 | finance.yahoo.comMineralys Therapeutics, Inc. (MLYS) Upgraded to Strong Buy: Here's What You Should KnowJanuary 6, 2024 | seekingalpha.comMLYS Mineralys Therapeutics, Inc.See More Headlines Receive MLYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mineralys Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today3/28/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MLYS CUSIPN/A CIK1933414 Webwww.mineralystx.com Phone888-378-6240FaxN/AEmployees12Year FoundedN/APrice Target and Rating Average Stock Price Target$37.00 High Stock Price Target$37.00 Low Stock Price Target$37.00 Potential Upside/Downside+184.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,900,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-26.48% Return on Assets-25.52% Debt Debt-to-Equity RatioN/A Current Ratio23.76 Quick Ratio23.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.87 per share Price / Book2.21Miscellaneous Outstanding Shares49,630,000Free FloatN/AMarket Cap$645.19 million OptionableOptionable BetaN/A Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Jon Congleton (Age 61)CEO & Director Comp: $428.87kMr. Adam Scott Levy (Age 46)CFO & Secretary Comp: $409.17kDr. David M. Rodman M.D. (Age 69)Chief Medical Officer Comp: $423.66kDr. Brian Taylor Slingsby M.D. (Age 47)M.P.H., Ph.D., Founder & Executive Chairman Ms. Cindy BerejikianExecutive Vice President of OperationsMs. Sarah FosterVice President of Human ResourcesDr. Robert McKean Ph.D.Senior Vice President of CMCMs. Danielle BradburySenior Vice President of Quality AssuranceMr. Jeffrey N. FellowsSenior Vice President of Regulatory AffairsMs. Jessica IbbitsonSenior Vice President of Clinical OperationsMore ExecutivesKey CompetitorsNeurogeneNASDAQ:NGNECalliditas Therapeutics AB (publ)NASDAQ:CALTNuvation BioNYSE:NUVBSilence TherapeuticsNASDAQ:SLNAcelyrinNASDAQ:SLRNView All CompetitorsInsiders & InstitutionsPNC Financial Services Group Inc.Bought 4,099 shares on 3/22/2024Ownership: 0.010%Vanguard Group Inc.Bought 40,342 shares on 3/11/2024Ownership: 2.380%Goldman Sachs Group Inc.Bought 45,585 shares on 3/1/2024Ownership: 0.111%American International Group Inc.Bought 2,692 shares on 2/28/2024Ownership: 0.023%Virtus ETF Advisers LLCBought 5,017 shares on 2/15/2024Ownership: 0.027%View All Insider TransactionsView All Institutional Transactions MLYS Stock Analysis - Frequently Asked Questions Should I buy or sell Mineralys Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mineralys Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MLYS shares. View MLYS analyst ratings or view top-rated stocks. What is Mineralys Therapeutics' stock price target for 2024? 2 brokerages have issued 1 year price targets for Mineralys Therapeutics' shares. Their MLYS share price targets range from $37.00 to $37.00. On average, they anticipate the company's stock price to reach $37.00 in the next year. This suggests a possible upside of 186.6% from the stock's current price. View analysts price targets for MLYS or view top-rated stocks among Wall Street analysts. How have MLYS shares performed in 2024? Mineralys Therapeutics' stock was trading at $8.60 at the beginning of 2024. Since then, MLYS shares have increased by 50.1% and is now trading at $12.91. View the best growth stocks for 2024 here. When is Mineralys Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our MLYS earnings forecast. How were Mineralys Therapeutics' earnings last quarter? Mineralys Therapeutics, Inc. (NASDAQ:MLYS) issued its earnings results on Thursday, March, 21st. The company reported ($0.61) EPS for the quarter, beating analysts' consensus estimates of ($0.85) by $0.24. When did Mineralys Therapeutics IPO? Mineralys Therapeutics (MLYS) raised $180 million in an IPO on Friday, February 10th 2023. The company issued 12,000,000 shares at a price of $14.00-$16.00 per share. Who are Mineralys Therapeutics' major shareholders? Mineralys Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Catalys Pacific LLC (22.37%), Vanguard Group Inc. (2.38%), Vanguard Group Inc. (2.38%), Sphera Funds Management LTD. (1.81%), Franklin Resources Inc. (1.70%) and Sectoral Asset Management Inc. (1.47%). Insiders that own company stock include Adam Scott Levy, David Malcom Rodman, Hbm Healthcare Investments (Ca, Jon Congleton, Ra Capital Management, LP and Samsara Biocapital Gp, Llc. View institutional ownership trends. How do I buy shares of Mineralys Therapeutics? Shares of MLYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MLYS) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research Advisory Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.